No Detail Found!

Effects on ALT normalization in the first month of treatment by Sofosbuvir/Ribavirin therapy versus Sofosbuvir/Daclatasvir therapy in HCV infected individuals

Author(s)
Tehmina Qamar Rawalpindi Medical University, Rawalpindi, Pakistan.
Shoaib Malik Sargodha Medical College, Sargodha, Pakistan.
Nadeem Naseem Biochemistry, Rawalpindi Medical University, Rawalpindi, Pakistan.
Kashif Rauf Biochemistry, Rawalpindi Medical University, Rawalpindi, Pakistan.
Bashir Ahmad International Islamic University, Islamabad (IIUI), Pakistan.
Naseer ud Din Rawalpindi Medical University, Rawalpindi, Pakistan
Abstract
Objective: To evaluate the effects on ALT normalization in the first month by SOFOS/RIB therapy versus SOFOS/DAC therapy in HCV infected individuals in Pakistan. Study Design: Cross-sectional comparative study. Material and Methods: A cross-sectional analysis was performed in a total of 200 Hepatitis C infected patients, sex, history of diabetes mellitus, prior interferon therapy, decrease in hemoglobin >2 gm/dl in 1st month and rise in serum bilirubin in 1st month was the qualitative variables and the quantitative variables were age, weight, baseline hemoglobin, baseline bilirubin at week 4 of treatment. The statistical relation of the mentioned variables was checked using SPSS version 15 on the basis of data collected. Results: Out of total 200 patients, 47% (94) were males, 53% (106) were females, 28% (56) patients were diabetic & 44.5% (89) patients had history of prior interferon therapy, 28.5% (57) patients were having low hemoglobin levels before starting above mentioned treatment. Both the groups completed the treatments A & B for 24 &12 weeks respectively & collected data showed the superiority of treatment B to treatment A as no decrease in hemoglobin (p=0.000), & no rise in serum bilirubin(p=0.000) during 1st month of treatment while serum bilirubin was 93 % in treatment B and 73 % in treatment A. Conclusion: The results concluded that treatment B (Sofosbuvir / Daclatasvir for 12 weeks) is superior antihepatitis C therapy as compared to the treatment A (Sofosbuvir / Ribavirin for 24 weeks) in order to achieve ALT normalization in the first month of therapy in Pakistani population. Ribavirin should be avoided to prevent hemolytic anemia as well.
Publication Details
Page(s) 208-212
DOI DOI not available
Published Journal: Journal of Rawalpindi Medical College, Volume: 23, Issue: 4, Year: 2019

Request the full text from PASTIC

Keywords
hepatitis C, Alkaline Phosphatase.
0

Citations

0

Downloads

77

Views